Molecular remission is an independent predictor of progression-free survival in patients with Waldenstrom macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study

被引：1

作者：

Varettoni, Marzia ^{[1
]}

Zibellini, Silvia ^{[1
]}

Merli, Michele ^{[2
]}

Drandi, Daniela ^{[3
]}

Jimenez, Cristina ^{[4
,5
]}

Furlan, Daniela ^{[6
]}

Ferretti, Virginia Valeria ^{[7
]}

Fabbri, Nicole ^{[8
]}

Dogliotti, Irene ^{[9
]}

Varraso, Chiara ^{[1
]}

Ferrante, Martina ^{[3
]}

Cappello, Emilia ^{[8
]}

Peri, Veronica ^{[9
]}

Cavalloni, Chiara ^{[1
]}

Borriero, Michela ^{[3
]}

Facchetti, Giulia Vittoria ^{[8
]}

Ferrero, Simone ^{[3
,9
]}

Arcaini, Luca ^{[1
,8
]}

Garcia-Sanz, Ramon ^{[4
,5
]}

机构：

[1] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy

[2] Univ Hosp Osped Circolo & Fdn Macchi ASST Sette L, Dept Hematol, Varese, Italy

[3] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[4] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, CIBERONC, Salamanca, Spain

[5] Canc Res Inst Salamanca IBMCC USAL CSIC, Salamanca, Spain

[6] Univ Insubria, Unit Anat Pathol, Varese, Italy

[7] Fdn IRCCS Policlin San Matteo, UOS Clin Epidemiol & Biostat, Pavia, Italy

[8] Univ Pavia, Dept Mol Med, Pavia, Italy

[9] Univ Torino, AOU Citta Salute & Sci, Hematol, Turin, Italy

来源：

HEMATOLOGICAL ONCOLOGY | 2023年 / 41卷 / 03期

关键词：

minimal residual disease; MYD88; progression-free survival; Waldenstrom Macroglobulinemia; MINIMAL RESIDUAL DISEASE; INTERNATIONAL WORKSHOP; RITUXIMAB; RECOMMENDATIONS; IMPACT;

D O I：

10.1002/hon.3082

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：574 / 577

页数：4

共 50 条

[1] Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia Treated with Ibrutinib
Castillo, Jorge J.
Gustine, Joshua
Demos, Maria
Keezer, Andrew
Meid, Kirsten
Chan, Gloria G.
Chen, Jiaji G.
Guerrera, Maria Luisa
Kofides, Amanda
Munshi, Manit
Tsakmaklis, Nicholas
BLOOD, 2019, 134
[2] IMPROVED COMPLETE REMISSION RATES AND SURVIVAL FOR PATIENTS WITH LARGE CELL LYMPHOMA TREATED WITH CHEMO-IMMUNOTHERAPY - A SOUTHWEST ONCOLOGY GROUP-STUDY
JONES, SE
GROZEA, PN
METZ, EN
HAUT, A
STEPHENS, RL
MORRISON, FS
TALLEY, R
BUTLER, JJ
BYRNE, GE
HARTSOCK, R
DIXON, D
SALMON, SE
CANCER, 1983, 51 (06) : 1083 - 1090
[3] Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?
Autore, Francesco
Tedeschi, Alessandra
Benevolo, Giulia
Mattiello, Veronica
Galli, Eugenio
Danesin, Nicolo
Rizzi, Rita
Olivieri, Jacopo
Cencini, Emanuele
Puccini, Benedetta
Ferrarini, Isacco
Marino, Dario
Bullo, Martina
Rossini, Bernardo
Motta, Marina
Innocenti, Idanna
Stirparo, Luca
Petrilli, Diego
Pasquale, Raffaella
Musto, Pellegrino
Scapinello, Greta
Noto, Alessandro
Peri, Veronica
Zamprogna, Giulia
Hohaus, Stefan
Frustaci, Annamaria
Piazza, Francesco
Ferrero, Simone
Laurenti, Luca
BLOOD, 2023, 142
[4] High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial.
Provencio, Mariano
Serna-Blasco, Roberto
Nadal, Ernest
Insa, Amelia
Rosario Garcia-Campelo, M.
Pereiro Corbacho, Diego
Domine, Manuel
Majem, Margarita
Rodriguez-Abreu, Delvys
Martinez-Marti, Alex
de Castro, Javier
Cobo, Manuel
Lopez-Vivanco, Guillermo
del Barco, Edel
Bernabe, Reyes
Vinolas, Nuria
Barneto, Isidoro
Viteri, Santiago
Pereira, Eva
Royuela, Ana
Casarrubios, Marta
Salas, Clara
Parra, Edwin R.
Wistuba, Ignacio
Calvo, Virginia
Laza-Briviesca, Raquel
Massuti, Bartomeu
Cruz-Vermudez, Alberto
Romero, Atocha
CANCER RESEARCH, 2021, 81 (13)
[5] Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenstrom macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study
Castillo, Jorge
Tedeschi, Alessandra
Tam, Constantine
Buske, Christian
Owen, Roger
Leblond, Veronique
Opat, Stephen
Branagan, Andrew
Sarosiek, Shayna
von Keudell, Gottfried
Treon, Steven
Allewelt, Heather
Chan, Wai
Schneider, Jingjing
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S274 - S274
[6] PROGNOSTIC FACTORS IN PROGRESSION-FREE SURVIVAL AND CORRECTED SURVIVAL IN PATIENTS WITH ADVANCED PROSTATIC-CANCER - RESULTS FROM A RANDOMIZED STUDY COMPRISING 150 PATIENTS TREATED WITH ORCHIECTOMY OR ESTROGENS
JOHANSSON, JE
ANDERSSON, SO
HOLMBERG, L
BERGSTROM, R
JOURNAL OF UROLOGY, 1991, 146 (05): : 1327 - 1333
[7] Obinutuzumab as Consolidation After Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance From Bone Marrow and Peripheral Blood Resulting in Improved Progression-Free Survival: Results of UK NCRI Phase II/III GALACTIC Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 16 - 17
[8] Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood resulting in improved Progression-free survival: Results of UK NCRI Phase II/III GALACTIC trial
Munir, Talha
Howard, Dena
Hockaday, Anna
Oughton, Jamie
Emmerson, Jake
Phillips, David
Neilson, Jeff
Pemberton, Nicholas
Paneesha, Shankara
Kennedy, Ben
Rawstron, Andrew
Hillmen, Peter
LEUKEMIA & LYMPHOMA, 2020, 61 : 209 - 210
[9] Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
Ren, Shengxiang
Xiong, Anwen
Yu, Jia
Wang, Xicheng
Han, Baohui
Pan, Yueyin
Zhao, Jun
Cheng, Yufeng
Hu, Sheng
Liu, Tianshu
Li, Yalun
Cheng, Ying
Feng, Jifeng
Yi, Shanyong
Gu, Shanzhi
Gao, Shegan
Luo, Yongzhong
Liu, Ying
Liu, Caigang
Duan, Huijie
Wang, Shuni
Yang, Xinfeng
Fan, Jia
Zhou, Caicun
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
[10] Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center.
Mo, Hongnan
Xu, Binghe
Ma, Fei
Li, Qing
Zhang, Pin
Yuan, Peng
Wang, Jiayu
Luo, Yang
Cai, Ruigang
Li, Qiao
Li, Yiqun
Guan, Xiuwen
Lin, Shaoyan
Chen, Yimeng
Wang, Zijing
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →